Keymed Biosciences Inc. (HKG:2162)

Hong Kong · Delayed Price · Currency is HKD

52.40

+4.40 (9.17%)

Mar 6, 2026, 4:08 PM HKT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
R&D and Commercialisation of Pharmaceutical Products	428.12M	354.10M	100.06M	110.27M	-
R&D and Commercialisation of Pharmaceutical Products Growth	20.91%	253.87%	-9.26%	-	-
Total	428.12M	354.10M	100.06M	110.27M	-
Total Growth	20.91%	253.87%	-9.26%	-	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Overseas	391.15M	353.19M	-	-	-
Overseas Growth	10.75%	-	-	-	-
Mainland China	36.97M	903.00K	100.06M	110.27M	-
Mainland China Growth	3994.57%	-99.10%	-9.26%	-	-
Total	428.12M	354.10M	100.06M	110.27M	-
Total Growth	20.91%	253.87%	-9.26%	-	-

Source: S&P Global Market Intelligence.